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Targeting the PD-1/PD-L1 immunologic checkpoint
with monoclonal antibodies has recently provided
breakthrough progress in the treatment of mela-
noma, non-small cell lung cancer, and other types
of cancer. Small-molecule drugs interfering with
this pathway are highly awaited, but their develop-
ment is hindered by insufficient structural informa-
tion. This study reveals the molecular details of the
human PD-1/PD-L1 interaction based on an X-ray
structure of the complex. First, it is shown that the
ligand binding to human PD-1 is associated with
significant plasticity within the receptor. Second, a
detailed molecular map of the interaction surface is
provided, allowing definition of the regions within
both interacting partners that may likely be targeted
by small molecules.
INTRODUCTION
The immune system has an important role in controlling cancer.
Tumor cells express cancer-specific antigens derived from
genetic alterations, and as such are targeted by the immune
cells. This response, however, is often inefficient, since tumors
can actively suppress immunity (Tumeh et al., 2014). One of
the mechanisms of that suppression involves interference with
immunologic checkpoints (inhibitory receptors) on immune cells
like, for example, the programmed death receptor 1 (PD-1),
whereby cancer cells present negative immunologic regulators
inducing exhaustion (loss of function) of antigen-specific effector
T cells (Phan et al., 2015; Herbst et al., 2014; Topalian et al.,
2015). A recent major breakthrough in cancer immunotherapy
has emerged in immunologic checkpoint blockade, utilizing
antibodies masking the inhibitory receptor PD-1 on immune
effector cells or PD-1 inhibitory receptor ligand (PD-L1) on tumor
cells, thereby alleviating cancer-induced immunosuppression
(Herbst et al., 2014; Schumacher et al., 2015). This represents
a major paradigm shift whereby the therapy aims at disinhibition
of native immune response compared with previous approachesStructure 23, 2341–23whereby tumor vaccines and recombinant cytokines aimed at
its de novo activation. Another receptor from the family of
immune-checkpoint receptors is the cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4). Ipilimumab, a CTLA-4-blocking
monoclonal antibody (mAb), became the first immune-check-
point receptor targeted therapy accepted by the US Food and
Drug Administration (FDA) in 2011 (Lipson and Drake, 2011;
Do¨mling and Holak, 2014). Unfortunately, ipilimumab therapy
is associated with frequent immune-mediated adverse events.
Recent clinical trials with mAbs targeting the PD-1/PD-L1
pathway demonstrated impressive tumor responses, cleaner
than mAbs against CTLA-4 (Lipson and Drake, 2011; Do¨mling
and Holak, 2014; Powles et al., 2014; Topalian et al., 2015;
Chen and Mellman, 2013; http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm436534.htm).
PD-1 is a type I transmembrane receptor that modulates
the activity of T cells in peripheral tissues. An activated T cell
expresses PD-1 on its surface upon antigen recognition and
produces interferons which induce expression of PD-L1 in
multiple tissues. Binding of PD-1 to its ligand limits T-cell activ-
ity. Thereby, under normal conditions, the PD-1/PD-L1 pathway
prevents excessive stimulation and maintains the immune
tolerance to self-antigens by negatively regulating the immune
response (Riella et al., 2012). However, PD-L1 is often overex-
pressed in different tumors including lymphoma, melanoma,
lung, breast cancer, glioblastoma, ovarian, kidney tumors, and
bladder cancers, which results in immune response handicap
within the tumor microenvironment (Sun et al., 2014; Muenst
et al., 2013; Ahmadzadeh et al., 2009; Matsuzaki et al., 2010;
Inman, 2007; Hawkes et al., 2015). The PD-1/PD-L1 interaction
inhibits T-lymphocyte proliferation, release of cytokines, and
cytotoxicity, resulting in exhaustion and apoptosis of tumor-
specific T cells (Wherry, 2011). Blockage of the PD-1/PD-L1
interaction results in reversal of exhausted T-cell phenotype
and normalization of antitumor response, providing the rationale
of targeted therapy (Sakuishi et al., 2010). It is expected that
similar reversal of exhausted T-cell phenotype may also provide
a therapeutic advantage in chronic viral infections (Barber et al.,
2006).
In clinics, a significant number of patients with melanoma
demonstrated long-term responses to anti-PD1 immuno-
therapy (Hamid et al., 2013). The results were impressive
enough to merit accelerated approval of nivolumab and48, December 1, 2015 ª2015 Elsevier Ltd All rights reserved 2341
Table 1. Data Collection and Refinement Statistics
Human PD-1/PD-L1
Complex
Apo-PD-1 Binding
Domain from hPD-L1
Data Collection
Space group P 31 2 1 C 2 2 21
Cell dimensions
a, b, c (A˚) 70.86, 70.86, 114.36 53.00, 54.71, 84.90
a, b, g () 90, 90, 120 90, 90, 90
Resolution (A˚) 61.37–2.45 (2.53–2.45)a 42.45–1.8 (1.86–1.8)a
Rmerge 0.043 (0.480)
a 0.065 (0.391)a
I/sI 35.22 (5.21)a 20.7 (4.9)a
Completeness (%) 99.98 (99.92)a 100 (100)a
Redundancy 10.6 (11.2)a 6.5 (6.7)a
Refinement
Resolution (A˚) 2.45 1.80
No. of reflections 12,708 11,799
Rwork/Rfree 0.2071/0.2527 0.1525/0.1777
No. of atoms
Protein 1,650 1,035
Ligand/ion 1 -
Water 15 75
Average B factors
Protein 57.60 17.50
Ligand/ion 50.10 -
Water 59.50 26.70
RMSDs
Bond lengths (A˚) 0.016 0.023
Bond angles () 1.77 2.23
aValues in parentheses represent the highest-resolution shell.pembrolizumab (both target PD-1 blocking its interaction with
PD-L1) by regulatory bodies in 2014 (Topalian et al., 2015;
Do¨mling and Holak, 2014; http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm436534.htm). Recent ev-
idence has even shown that anti-PD-1 therapy is superior
to chemotherapy in the treatment of metastatic melanoma
(Moreno and Ribas, 2015; Mahoney et al., 2015; Chen and
Mellman, 2013). Nivolumab has also demonstrated unprece-
dented results in a clinical trial in metastatic squamous non-
small cell lung cancer (NSCLC). It has recently gained FDA
acceptance in this indication, becoming the first monotherapy
in more than 15 years to demonstrate proven superior overall
survival compared with the standard of care (http://www.fda.
gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm436566.
htm). Anti-PD-L1 immunotherapy is at the earlier stage of clin-
ical development; nevertheless, several tested antibodies have
also demonstrated highly encouraging results. Objective tumor
responses were observed in early-phase clinical trials in mela-
noma, NSCLC, and several other solid tumors (Brahmer et al.,
2012). Results obtained in a phase I clinical trial of patients
with metastatic urothelial bladder cancer were so impressive
(tumor shrinking was observed in 43% of patients) that the
FDA granted a breakthrough designation for the tested antibody
(Powles et al., 2014). It is currently widely expected that thera-2342 Structure 23, 2341–2348, December 1, 2015 ª2015 Elsevier Ltdpies directed against negative immunologic regulators (check-
points) are likely to soon become a significant component of
treatment for a variety of malignancies.
The excitement within the field encourages the development
of small-molecule inhibitors of the PD-1/PD-L1 interaction that
could likely overcome the typical drawbacks of the antibody-
based immunotherapies, including certain side effects. This,
however, is hindered, among other factors, by the incomplete
structural information about these proteins. The structures of
the complexes of the murine PD-1 and human PD-L1 (Lin
et al., 2008) and that of the murine PD-1 and murine PD-L2
(La´za´r-Molna´r et al., 2008; Freeman, 2008), published in
2008, established the structural foundations of the PD-1/PD-
L1, -2 interactions. These structures have not allowed, how-
ever, for assessment of the extent of plasticity in these interac-
tions when starting from the apoprotein components of the
complexes. The crystal structure of the extracellular domain
of human PD-1 alone has only been determined recently
PDB: 3RRQ. Despite the fact that the murine PD-1 binds hu-
man PD-L1, the sequence identity between human and murine
PD-1 is only 64%, indicating likely differences in the details of
the binding modes (Figure S1). Herein, we report the crystal
structure of the human PD-1/human PD-L1 complex, which
indeed documents significant differences in the binding be-
tween murine and human PD-1 and the ligand (hPD-L1). We
also present a comprehensive comparison of the structures
of the PD-1/PD-L1 complexes from different species and their
components alone. This information allowed us to define fea-
tures of the hot-spot pockets in human PD-1/PD-L1 required
for inhibition of this interaction. The proposed pharmacophore
model for this protein-protein interaction should provide a solid
starting point for the design of chemical probes and potential
small-molecule therapeutics targeting the PD-1/PD-L1 axis.
RESULTS
Overall Structure of the Human PD1/PD-L1 Complex
Crystals of the hPD-1/hPD-L1 complex that we obtained dif-
fracted to 2.45 A˚ resolution and contained a single complex
assembly in the asymmetric unit (Table 1). PD-1 assumes a
b-sandwich immunoglobulin-variable (Ig V)-type topology with
Cys54 and Cys123 forming a characteristic disulfide bridge;
however PD-1 lacks the second disulfide common to other fam-
ily members (CD28, CTLA-4, and ICOS). The molecule is well
defined by electron density, safe for a region between C0D
strands (Asp85–Asp92) (canonical Ig-strand designations are
used; Figure S2). There is no indication of the PD-1 dimerization
within the crystal lattice, consistent with its monomeric form in
solution in previous reports (La´za´r-Molna´r et al., 2008; Zhang
et al., 2004; Cheng et al., 2013).
Similarly to PD-1, the interacting, N-terminal domain of PD-L1
is also characterized by the Ig V-type topology. The entire mole-
cule is well defined by its electron density. The arrangement of
the molecules within the crystal lattice does not suggest dimer-
ization of PD-L1 as has been presented in previous studies.
PD-1 and PD-L1 form a 1:1 complex within the crystal,
consistent with the stoichiometry determined by us and others
in solution (Lin et al., 2008; Cheng et al., 2013). This resolves
the ambiguity concerning complex stoichiometry brought byAll rights reserved
Figure 1. Binding of hPD-L1 Induces Significant Structural Rearrangements within the Structure of hPD-1
Within the complex structure, hPD-1 is colored blue and hPD-L1 is colored green; both are shown in stereo view in ribbon representation. Apo-hPD1 (PDB: 3RRQ)
was overlaid on hPD-1 within the complex, and residues 62–82 of the former are shown (yellow ribbon). The structural rearrangement within the CC0 loop upon
complex formation is clearly discernible.the mPD-1/hPD-L1 structure where 2:1 stoichiometry was
observed, although the interaction of one of the mPD-1 mole-
cules was arbitrarily considered by the authors a crystallization
artifact due to limited interaction surface (Lin et al., 2008). The
1:1 stoichiometry contrasts that observed within CTLA-4 com-
plexes with its ligands, where both interacting partners form
homodimers (Stamper et al., 2001; Schwartz et al., 2001). The
interaction of PD-1 and PD-L1 resembles that of Ig V domains
within antibodies and T-cell receptors being mediated by the
strands from the front faces of interacting domains (GFCC0
b sheets). This places the two interacting partners roughly
orthogonally such that the Ig V loops (CDR loops) do not take
part in the interaction (as opposed to CTLA-4 interaction with
its ligands where CDR loops provide the interaction surface),
but rather form a structure resembling that of an antigen-binding
site within antibodies. Consistently, the CDR3 (FG) loop impor-
tant in the interaction of CTLA-4 with its ligands is not involved
in PD-1/PD-L1 binding (Lin et al., 2008).
Ligand Binding Induces Conformational Changes
within hPD-1
The crystal structure of apo-hPD-L1 in a monomeric form was
determined here for reference, and is almost identical to that
in the dimeric state PDB: 4Z18. The overall structure of apo-
hPD-1 PDB: 3RRQ and the structures of apo-hPD-L1 deter-
mined by us and others (Zhang et al., 2004; Lin et al., 2008;
Chen et al., 2010; and PDB: 4Z18) resemble those observed
within the complex in this study. A more detailed analysis, how-
ever, demonstrates that complex formation involves significant
structural flexibility, especially within hPD-1. The structure of
apo-hPD-1 and the structure of hPD-1 extracted from the
complex described within this study overlay relatively well
(root-mean-square deviation [RMSD] of 0.388 A˚) except for
the CC0 loop (Met70-Asp77) (Figure 1). The loop is found in
an open conformation in the apo-PD-1 structure where Met70
and Ser71 form a part of a C b strand within an antiparallel
CF b sheet, and all the side chains within the loop point
away from the ligand binding site. Complex formation induces
loop rearrangement in a form of a 90 twist and associated
5 A˚ displacement of Ca carbons. This results in even more
pronounced displacements of the side-chain atoms. The N
ε2Structure 23, 2341–23atom of Gln75 in free hPD-1 structure is located 18 A˚ away
from where the backbone atoms of LArg125 (the L symbol
within amino acid designation refers to PD-L1) are located
in the overlaid structure of the complex, whereas the side
chain of Gln75 participates in hydrogen bonds with the back-
bone oxygen and amide of LArg125 within the complex. This
rearrangement additionally allows hydrogen bond formation
between the side chains of Gln75 and LAsp26. In turn, the
side-chain hydroxyl oxygen of Thr76 is translated by 6 A˚ to
facilitate hydrogen bond formation with the backbone carbonyl
oxygen of LTyr123. A similar shift is observed for the backbone
carbonyl oxygen of Thr76, which enables hydrogen bond
formation with the side-chain amine of LLys124. The C and F
b-sheet contacts mediated by Met70 and Ser71 in the apo-
hPD-1 structure are lost during the CC0 loop rearrangement.
Overall, the CC0 loop, found in an open conformation in apo-
hPD-1, closes around hPD-L1, allowing formation of four
hydrogen bonds. We hypothesize that this loop closure stabi-
lizes the initial transient interaction of hPD-1 and hPD-L1. Inter-
estingly, however, in the structure of apo-mPD-1 the CC0 loop
displays a closed conformation, similar to that observed within
the hPD-1/hPD-L1 and mPD-1/hPD-L1 complexes. Therefore,
the described CC0 loop rearrangement is specific to human
PD-1 only.
In contrast to hPD-1, the complex formation-associated plas-
ticity within hPD-L1 involves only minor adjustments in the
arrangement of the side chains contributing to the interaction
surface and no significant changes within the backbone. The
most pronounced movements involve the side chains of
LGlu58, LMet115, LTyr123 (which form a hydrophobic pocket
accommodating Ile134), LIle54, and LAla121. The majority of
observed displacements, however, does not exceed 3 A˚ for
the most distal side-chain atoms and, as such, may all be
considered as minor adjustments imposed by local steric con-
straints of the interaction surface. Only the side chain of
LArg113 displays a 5 A˚ movement of the distal atoms. This
allows formation of an intermolecular salt bridge with the side
chain of Glu136 and another hydrogen bond with the side chain
of LGlu58. It is, however, poorly justified to speculate on the
significance of the observed adjustment within the LArg113
side chain in complex formation, since the orientation of this48, December 1, 2015 ª2015 Elsevier Ltd All rights reserved 2343
Figure 2. Close-Up Views of the hPD-1/hPD-L1 Interface
hPD-1 and hPD-L1 are represented by blue and green ribbons, respectively. All residues important for the interaction are highlighted as sticks. Residues forming
the hydrophobic core are colored yellow. Water molecules are shown as red spheres. Hydrogen bonds are depicted as black dashed lines.
(A) Front-side view.
(B) Back-side view.residue is likely affected by crystal packaging in the structure of
apo-hPD-L1. Moreover, LArg113 assumes a yet different confor-
mation within the mPD-1/hPD-L1 structure.
Detailed Analysis of the Receptor-Ligand Interactions
The crystal structure determined in this study demonstrates
that the receptor-ligand interaction is mediated in its major
part by residues of C0CFG strands within both PD-1 and PD-
L1 (Figure 2). The protein-protein contacts involve both hydro-
phobic interactions and polar interactions, and bury a total
surface area of 1,970 A˚2. The interaction is constructed
around a central hydrophobic core contributed by both part-
ners and constituted by nonpolar residues in the front sheet
of PD-1 (Val64, Ile126, Leu128, Ala132, Ile134) and those of
the front sheet of PD-L1 (LIle54, LTyr56, LMet115, LAla121,
LTyr123), including a characteristic alkyl-p interaction of the
side chains of Ile134 and LTyr123. This hydrophobic region
is open to the solvent on the would-be antigen-binding site,
and is neighbored by a buried region of mixed polar/nonpolar
interactions on the opposite side of the molecule. Both these
regions are surrounded by a peripheral network of polar
residues (safe on the CDR loop side) providing additional
hydrogen bond-mediated interactions between the receptor
and the ligand.
The region of mixed polar/nonpolar contacts buried deep
within the binding interface consists of a pronounced p-p stack-
ing interaction between the side chains of Tyr68 and LTyr123
where the two phenol groups are oriented antiparallel, thereby
optimizing dipolemomentum (Figure S3). In addition, the hydrox-
yl within the side chain of Tyr68 makes a hydrogen bond contact
with the side-chain carboxyl of LAsp122, and a comparable con-
tact is observed between the side-chain hydroxyl of LTyr123
and the side-chain carboxyl of Glu136, which makes this entire
interaction region roughly pseudo-symmetrical. Furthermore,
a buried hydrogen bond between the side chain of Asn66 and
the carbonyl main-chain oxygen of LAla121 additionally contrib-
utes to the hPD-1/hPD-L1 interaction.
The polar interactions located at the periphery of the interface
and, therefore, partially exposed to the solvent, include a2344 Structure 23, 2341–2348, December 1, 2015 ª2015 Elsevier Ltdhydrogen bond between the backbone amide of Ala132 and
side-chain carbonyl atom of LGln66, water-mediated interac-
tions between the backbone amide and carbonyl of Ile134 and
LTyr56 hydroxyl and LGlu58 carboxyl, and a salt bridge main-
tained between Glu136 and LArg113 at the front side of the com-
plex (Figure 2A). Hydrogen bonds connecting the side chain of
Thr76 and backbone carbonyl oxygen of LTyr123, the side chain
of Gln75 and backbone amide and carbonyl of LArg125, and an
additional hydrogen bond between the side chains of Gln75 and
LAsp26 form the interactions at the side of the complex opposite
to the CDR loops. Furthermore, hydrogen bonds between the
backbone carbonyl oxygen of Thr76 and the side-chain amine
of LLys124, the side-chain amine of Lys78 and backbone
carbonyl oxygen of LPhe19, and a water-mediated interaction
of the side chain of Asn66 and the main-chain carbonyl oxygen
of LAla121 stabilize the interaction on the back side of the com-
plex (Figure 2B).
DISCUSSION
Given the spectacular results obtained in clinics by the
antibodies that target the PD-1/PD-L1 axis and the fact that
small-molecule inhibitors of protein-protein interactions proved
promising drug candidates, it is not surprising that groups
in academia, pharmaceutics, and biotech companies have
ongoing projects on the PD-1 small-molecule inhibitors. None
of these groups, however, including ours, have reported such in-
hibitors until now. One of the reasons for this may have been that
the structural information derived from the complex with murine
PD-1 suggested a pharmacophore for the design of leads for
PD-1 that, in light of our structure of the human complex, may
not have been suitable for finding small molecules that bind to
the human protein.
The protein-protein interaction surface is notoriously difficult
to target with small molecules, and usually the structures of
individual components are not sufficient to guide rational
inhibitor design. This is because the hydrophobic interaction
surface found within the complex is often involved in cry-
stal contacts in the apo forms, which may result in certainAll rights reserved
Figure 3. Gly124 Cleft (LTyr123-Accommo-
dating Cavity) andCC0 LoopRearrangement
Are Induced by hPD-L1 Binding to hPD-1
(A and B) Surface representation of the hPD-L1
binding site of hPD-1. (A) Apo-hPD-1. (B) hPD-1
complexed with hPD-L1. The CC0 loop is marked
by the blue circle, the LTyr123-accommodating
cavity (i.e. the Gly124 cleft) is marked by a cyan
circle; Tyr68 and Glu136 are marked in yellow and
green, respectively.
(C and D) Cross sections through CC0 loop (blue
line) and Gly124 cleft (cyan line) of hPD-1 struc-
tures shown in (A) and (B), respectively, depicting
rearrangement of the interaction surface upon
ligand binding.artifactual conclusions. Moreover, significant plasticity within
the components usually accompanies the complex formation.
Therefore, complete information is provided only by comparing
experimentally determined structures of components in their
apo forms (preferably in multiple crystal forms) and their
complex. To this end, the structure of mPD-1/hPD-L1 complex
has been determined previously. However, relatively low seq-
uence identity of mouse and human PD-1 suggested likely
differences in the detailed binding modes. Consistently, the
structures of apo-hPD-1 and that of its murine ortholog are
dissimilar in that the human receptor lacks a C00 strand within
its Ig V-type fold (which is replaced by a flexible loop connect-
ing the C0 and D strands), the BC loops adopt different confor-
mations, and some important residues forming the interaction
surface are different within the orthologs. Therefore, although
mutagenesis studies and nuclear magnetic resonance (NMR)
data have suggested that the overall binding mode of hPD-1
and hPD-L1 is consistent with that of mouse-derived receptor
and a human-derived ligand, the detailed molecular features of
the former interaction have remained unknown prior to this
study.
Here, we show that structural differences between human
and murine apo-PD-1 correspond to certain differences within
the detailed binding modes to hPD-L1. First, the interaction
surface within the human complex is notably different from
that published previously for the m/h complex (Figure S3). Sec-
ond, plasticity in the PD-1 receptor is seen in the complex for-
mation within human protein, which is not the case for the m/h
complex. Comparison of the interaction surface between apo
and complexed hPD-1 (Figure 3) shows changes associated
with remodeling upon binding of the ligand. The surface
segment formed by Tyr68, Ile134, and Glu136 in the apoprotein
undergoes rearrangement upon ligand binding. LTyr123 forces
the deepening of the cleft by jostling Leu122, Cys123, and
Gly124 residues of the F strand, thereby changing the position
of the side chain of Ile134 (and Glu136) and enforcing closure of
the CC0 loop (Figures 1 and 3). These data allow for determiningStructure 23, 2341–2348, December 1, 2015 ªthe hPD1/hPD-L1 protein-protein inter-
action hot spots (Guo et al., 2014;
Koes et al., 2012).
The hPD-1 hot spots are mostly hydro-
phobic and comprise Asn66, Tyr68,
Gly124, Ile126, Leu128, Ile134, andGlu136 located in the front sheet of hPD-1. The most distinctive
feature of this segment is the hydrophobic cleft at Gly124. The
interface here relies on the steric complementarity between the
PD-1 cleft and the hydrophobic face of the hPD-L1 and, in partic-
ular, on LTyr123, which inserts deep in the Gly124 cleft. With the
aromatic ring of Tyr68 on one side and the backbone of Glu136
on the other side of the groove, the cleft is a perfect spot for
anchoring an aromatic ring. Pointing toward Asn66, Ile126, and
Leu128 in one direction and toward Met70-Asp77 to close the
CC0 loop in another, such a chemical probe may easily cover
almost all important interactions within the Gly124 anchor site.
The fragment-based lead design has become an important
and powerful approach in structure-based lead discovery
(reviewed in Hajduk and Greer, 2007; Murray et al., 2012).
Starting fragments have low molecular mass (<300 Da), and
although the binding interactions of these fragments with
target proteins are weak (in the millimolar range), they
are structurally understood through X-ray crystallography or
NMR and exhibit high ‘‘ligand efficiency’’. For example, tyro-
sine derivatives that mimic the anchor residue LTyr123 that fills
the Gly124 pocket in the PD-1/PD-L1 complex should in prin-
ciple be an excellent building block of such fragments. We
have tested a limited number of tyrosine derivatives for their
anticipated interaction with hPD-1, but without success (Table
S1). In the structure of the apo-PD-1, the pocket we attemp-
ted to target is only partly formed owing to the intrinsic flexi-
bility of the CC0 loop. Since the ‘‘open conformation’’ of the
CC0 loop in PDB: 3RRQ is partly stabilized by crystal packing,
it may not be excluded that there is an ensemble of open and
closed conformations of the CC0 loop of human PD-1 in solu-
tion. Targeting the transient states of this pocket with frag-
ments may therefore be challenging. Fragment ligands with
weak affinities might not provide sufficient binding free energy
to sustain permanent loop closure that hPD-1 exhibits when
binding to hPD-L1, which generates a favorable binding
pocket on an otherwise relatively flat surface. A larger number
of analogs needs to be tested, however, to confirm such a2015 Elsevier Ltd All rights reserved 2345
Figure 4. Three Main Hot Spots on the PD-L1 Surface
The deepest cleft comprises LTyr56, LGlu58, LArg113, LTyr123, and LMet115.
The second hot spot is formed by LMet115, LAla121, and LTyr123. The third hot
spot, constituted by a shallow groove, is composed of LAsp122-LArg125 and
LAsp26. Residues from hPD-1 are colored blue, hPD-L1 is represented by gray
surface, and the hot spots are marked by yellow circles. General orientation of
the PD-1/PD-L1 complex is represented in the bottom left corner.hypothesis. Also, larger small molecules may possibly more
easily mimic the effect of the binding of PD-L1 to PD-1 (i.e.,
the fragments that additionally interact with the residues of
the CC0 loop).
Within the hPD-1 interaction surface of hPD-L1 we identified
three major hot spots, two of which are expected to form a drug-
gable pharmacophore (Figure 4). The first is a classical pocket
of mostly hydrophobic character accommodating Ile134. This
pocket is composed of the side chains of LTyr56, LGlu58,
LArg113, LMet115, and LTyr123, and is of perfect size and prop-
erties to accommodate a six-membered aromatic ring (we
designate this pocket the Ile134 pocket). The second hot spot
is located just nearby and accommodates Ile126. It is composed
of LMet115, LAla121, and LTyr123, and could likely be effectively
filled by a branched aliphatic moiety, which could anchor with a
terminal hydrogen bond donor group at carbonyl oxygen of
LAla121. The third hot spot is an extended groove accommoda-
ting Tyr68, Gln75, and Thr76. It is formed by the main chain and
the side chains spanning residues LAsp122 to LArg125, and is
flanked by the side chain of LAsp26. Multiple hydrogen bond do-
nors and acceptors are available within the groove, which is,2346 Structure 23, 2341–2348, December 1, 2015 ª2015 Elsevier Ltdhowever, relatively shallow and may be hard to efficiently target
with small-molecule probes.
In summary, the data presented here provide the structural ba-
sis for the rational design of small-molecule therapeutics that
disrupt the PD-1/PD-L1 interaction.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The interacting extracellular domains of hPD-1 (residues 33–150; UniProt:
Q15116; cysteine at position 93 was replaced with serine to aid protein stability)
and hPD-L1 (residues 18–134; UniProt: Q9NZQ7) were cloned into pET-24d and
pET-21b, respectively and expressed in Escherichia coli BL21 (DE3) in the form
of inclusion bodies (IB). IB were collected, washed, and dissolved in buffered
guanidine hydrochloride. Both proteins were refolded by dropwise dilution fol-
lowed by dialysis, and purified to homogeneity by gel filtration. The purity and
protein folding were evaluated by SDS-PAGE and NMR, respectively.
Crystallization of the hPD-1/hPD-L1 Complex and Apo-hPD-L1
Purified hPD-1 and hPD-L1 were mixed in 1:1 molar ratio, and the complex
was purified by gel filtration in 10 mM Tris (pH 8.0) containing 20 mM NaCl.
Complex-containing fractions were pooled and concentrated to 3 mg/ml.
Diffraction-quality crystals were obtained at room temperature from 0.1 M
Bis-Tris (pH 5.5) containing 1.84 M ammonium sulfate using a sitting-drop
vapor diffusion setup. Apo-hPD-L1 was concentrated to 5 mg/ml, and diffrac-
tion-quality crystals were obtained from 1.80 M sodium formate using similar
methodology.
Structure Determination and Refinement
Crystals were flash-cooled in liquid nitrogen after cryoprotection. The diffrac-
tion data were collected at the Helmholtz Centrum 14.1 beamline at BESSY
(Berlin, Germany; Mueller et al., 2015). The data were indexed and integrated
using XDS (Krug et al., 2012; Kabsch, 2010), and scaled and merged using
Scala (Evans, 2006). The initial phases were obtained by molecular replace-
ment calculated using Phaser (McCoy et al., 2007). The models were manually
built in the resulting electron density maps using Coot (Emsley et al., 2010).
Restrained refinement was performed using Phenix (Adams et al., 2010) and
Refmac 5.0 (Murshudov et al., 2011). The final models were deposited in the
PDB under accession numbers PDB: 4ZQK and 5C3T.
Details of the expression and purification of hPD-1 and hPDL-1, crystalliza-
tion of the hPD-1/hPD-L1 complex and apo-hPD-L1, and structure solution
and refinement are described in Supplemental Experimental Procedures.
Data collection and refinement statistics are summarized in Table 1.
ACCESSION NUMBERS
Coordinates and structure factors have been deposited in the PDB under
accession codes PDB: 4ZQK and 5C3T.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.str.2015.09.010.
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